https://www.selleckchem.com/pr....oducts/LY2228820.htm
Aim To re-optimize the pneumococcal (Pn) electrochemiluminescence (ECL) assay and to validate and bridge the enhanced assay to the WHO ELISA, to support the Phase III clinical trial program for V114, a 15-valent Pn conjugate vaccine. Materials methods The Pn ECL assay was re-optimized, validated and formally bridged to the WHO ELISA. Results The enhanced Pn ECL assay met all prespecified validation acceptance criteria and demonstrated concordance with the WHO ELISA. The corresponding threshold value remains at 0.35 μg/ml for all
Like
Comment
Share
